Pink Sheet Podcast: Pre-Announced FDA Inspections, Vaccine Safety, On-Time Application Decisions
Source : 'The Pink Sheet'
Pink Sheet senior writers Derrick Gingery and Sarah Karlin-Smith, Senior Editor Joanne Eglovitch and Executive Editor Nielsen Hobbs consider the impact of pre-announcing domestic inspections once the pandemic ends, look at the COVID-19 vaccine adverse event systems, and discuss new data on the US Food and Drug Administration’s on-time decision rates during the pandemic.
US FDA Mulls Possibility Of Preannouncing Post-COVID Domestic Surveillance Inspections
All of the stories on the one-year anniversary of the COVID-19 pandemic from the Informa Insights publications
US FDA's On-Time Review Decision Rates Slip During The Pandemic, Especially For Biosimilars
By Pink Sheet Team